三鑫医疗(300453) - 2023 Q3 - 季度财报

Financial Performance - Revenue for Q3 2023 reached ¥348,215,464.05, an increase of 7.36% compared to the same period last year[4] - Net profit attributable to shareholders was ¥51,930,445.97, up 37.42% year-on-year[4] - Net profit excluding non-recurring items was ¥49,166,552.09, reflecting a 40.20% increase compared to the previous year[4] - Total operating revenue for Q3 2023 was CNY 929,961,012.41, a decrease of 5.5% compared to CNY 984,555,678.59 in the same period last year[20] - Net profit for Q3 2023 was CNY 152,007,133.72, slightly down from CNY 152,862,245.06 in Q3 2022, representing a decrease of 0.56%[21] - Total profit for Q3 2023 was CNY 171,860,267.98, down from CNY 175,965,889.48 in Q3 2022, a decrease of 2.4%[21] - Earnings per share (EPS) for Q3 2023 was CNY 0.2737, compared to CNY 0.2759 in the previous year[21] Cash Flow - Cash flow from operating activities for the year-to-date was ¥209,634,330.47, showing a significant increase of 61.70%[8] - The company reported a 61.70% increase in cash flow from operating activities year-to-date, primarily due to reduced cash payments for goods purchased[8] - Operating cash flow for the period was ¥209,634,330.47, an increase of 61.7% compared to ¥129,645,902.65 in the previous period[23] - Cash received from sales of goods and services was ¥1,004,748,423.15, a decrease of 5.0% from ¥1,058,219,957.04 in the previous period[23] - Cash paid for purchasing goods and services was ¥480,834,683.31, down from ¥630,407,469.61 in the previous period[23] - Cash received from tax refunds was ¥3,042,749.87, significantly lower than ¥11,375,059.90 in the previous period[23] - Cash paid to employees was ¥175,143,239.20, slightly up from ¥170,790,497.04 in the previous period[23] Assets and Liabilities - Total assets as of September 30, 2023, amounted to ¥1,941,041,580.57, representing an 8.65% increase from the end of the previous year[4] - Current assets totaled CNY 704,863,915.04, up from CNY 689,282,923.80 at the start of the year, with cash and cash equivalents decreasing to CNY 198,642,770.84 from CNY 320,332,008.17[16] - Total liabilities reached CNY 704,863,915.04, with current liabilities including accounts payable at CNY 144,065,193.05, down from CNY 149,663,372.50[17] - Total liabilities increased to CNY 692,805,153.51, up from CNY 631,130,435.41 year-on-year, reflecting a growth of 9.7%[20] - Total equity rose to CNY 1,248,236,427.06, an increase from CNY 1,155,405,237.88, marking a growth of 8.0%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,692[11] - The company reported a total of 157,780,477 shares under lock-up agreements, with key shareholders maintaining their shares under a 75% lock-up policy[14] Investment and Expenses - The company’s financial expenses decreased by 407.02% year-on-year, mainly due to increased interest income from deposits[8] - The company’s investment income increased by 92.94% year-on-year, attributed to higher wealth management returns[8] - Research and development expenses increased to CNY 34,200,080.78, up from CNY 30,215,477.20, indicating a growth of 13.2%[20] - The company reported a decrease in financial expenses, with a net financial cost of CNY -1,924,918.99 compared to CNY -379,656.56 in the previous year[20] Strategic Initiatives - The company has not reported any new product launches or significant technological advancements in this quarter[15] - There are no updates on market expansion or mergers and acquisitions during this reporting period[15] - The company has not provided specific guidance for future performance or strategic initiatives in the upcoming quarters[15]